Journals / Fırat Üniversitesi Sağlık Bilimleri Veteriner Dergisi / 2013 / Cilt: 27 - Sayı: 1

A new macrolide in veterinary medicine: Tulathromycin

Veteriner hekimlikte yeni bir makrolid: Tulatromisin

Pages
53–56
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, general and pharmacological properties of tulathromycin, spectrum of effect, usage, dosage, indication, side effects and toxicity was emphasized in the light of the current literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Tulathromycin is a new product with a lactone ring, a broad spectrum semi-synthetic macrolide.
📊
Key Findings & Data:It is administered at a dose of 2.5 mg/kg/bw as single dose subcutaneous in cattle and intramuscular in swine.
💡
Conclusion & Impact:In this review, general and pharmacological properties of tulathromycin, spectrum of effect, usage, dosage, indication, side effects and toxicity was emphasized in the light of the current literature.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Tulathromycin is a new product with a lactone ring, a broad spectrum semi-synthetic macrolide. It is administered at a dose of 2.5 mg/kg/bw as single dose subcutaneous in cattle and intramuscular in swine. It is used for the treatment and control of bovine respiratory disease caused Pasteurella haemolytica, Pasteurella multocida, Haemophilus somnus, Actinobacillus pleuropneumonia, Mycoplasma hyopneumonia and Mycoplasma bovis and swine respiratory disease caused Actinobacillus pleuropneumonia, Pasteurella multocida and Mycoplasma hyopneumonia. In this review, general and pharmacological properties of tulathromycin, spectrum of effect, usage, dosage, indication, side effects and toxicity was emphasized in the light of the current literature.

Özet

Tulatromisin lakton halkasına sahip, geniş spektrumlu, yarı sentetik, makrolid grubu yeni bir üründür. Sığırlarda deri altı ve domuzlarda kas içi 2.5 mg/kg/canlı ağırlık tek doz olarak uygulanmaktadır. Sığırlarda Pasteurella haemolytica, Pasteurella multocida, Haemophilus somnus, Actinobacillus pleuropneumonia, Mycoplasma hyopneumonia ve Mycoplasma bovis’in, domuzlarda Actinobacillus pleuropneumonia, Pasteurella multocida ve Mycoplasma hyopneumonia’nın neden olduğu solunum sistemi hastalıklarının tedavisi ve korunmasında kullanılmaktadır. Bu derlemede, güncel literatürler ışığında tulatromisinin genel ve farmakolojik özellikleri, etki spektrumu, kullanım şekli, dozu, endikasyonu, yan etkileri ve toksisitesi üzerinde durulmuştur.

🔖

Cite This Article

GÜL, B. B. (2022). A new macrolide in veterinary medicine: Tulathromycin. Fırat Üniversitesi Sağlık Bilimleri Veteriner Dergisi, Cilt: 27 - Sayı: 1, 53–56. https://ajindex.com/articles/515134

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Anon. "Draxxin (tulathromycin) injectable solution". http://www.draxxin.com/PAHimages/compliance_pdfs/US_ EN_DR_Compliance.pdf/ 02.01.2009
  2. Anon. "Annex I- Summary of product characteristics". http://www.ema.europa.eu/ 05.11.2012
  3. Brown SA. Tulathromycin Solution for Parenteral Injection for Treatment of Swine and Bovine Respiratory Disease. http://www.fda.cvm/Documents/Brown.ppt/ 02.01.2009
  4. Anon. “Food and Drug Administration (FDA). Tulathromycin solution for parenteral injection for treatment of bovine and swine repiratory diseases. Maryland (USA), 2004”. http://www.fda.gov/ 05.01.2009
  5. Hart FJ, Kilgore RW, Meinert TR, et al. Efficacy of tulathromycin in the treatment of respiratory disease in pigs caused by Actinobacillus pleuropneumoniae. J Vet Rec 2006; 158: 433-436
  6. Carrie DF, Jennifer KB, Cheryl GZ, et al. Antiinflammatory benefits of antibiotic-induced neutrophil apoptosis: tulathromycin induces caspase-3-dependent neutrophil programmed cell death and inhibits NF-B signaling and CXCL8 transcription. Antimicrob Agents Ch 2011; 55: 338-348
  7. Anon. “Draxxin”. www.pfizer.com.tr/pfizer/tr/UploadedPdf/ 308.pdf/ 26.12.2008
  8. EMEA. “Committee for Veterinary Medicinal Products: Tulathromycin-Summary Report (2). European Agency for the Evaluation of Medicinal Products, London (GB), 2004”. http://www.emea.europa.eu/pdfs/vet/mrls/089404en.pdf/ 26.12.2008
  9. EMEA. “Committee for Veterinary Medicinal Products: Tulathromycin-Summary Report (1). European Agency for the Evaluation of Medicinal Products, London (GB), 2002”. http://www.emea.europa.eu/pdfs/ vet/mrls/084202en.pdf-2008-11-25/ 26.12.2008
  10. Gáler D, Hessong S, Beato B, et al. An analytical method for the analysis of tulathromycin, an equilibrating triamilide, in bovine and porcine plasma and lung. J Agric Food Chem 2004; 52: 2179-2191
  11. Evans NA. Tulathromycin: an overview of a new triamilide antibiotic for livestock respiratory disease. J Vet Ther 2005; 6: 83-95
  12. Norcia LJ, Silvia AM, Santoro SL, et al. In vitro microbiological characterization of a novel azalide, two triamilides and an azalide ketal against bovine and porcine respiratory pathogens. J Antibiot (Tokyo) 2004; 57: 280- 288
  13. Retsema JA, Brennan LA, Girard AE. Effects of environmental factors on the in vitro potency of azithromycin. Eur J Clin Microbiol Infect Dis 1991; 10: 834- 842
  14. Letavic MA, Bronk BS, Bertsche CD, et al. Synthesis and activity of a novel class of tribasic macrocyclic antibiotics: